Revenue, 2025

USD 38.42 Billion

Forecast, 2035

USD 107.53 Billion

CAGR, 2026-2035

10.84%

Report Coverage

United States

U.S. Non-Invasive Cancer Diagnostics Market Trends for 2026

The U.S. non-invasive cancer diagnostics market size was estimated at USD 38.42 billion in 2025 and is predicted to increase from USD 42.58 billion in 2026 to approximately USD 107.53 billion by 2035, expanding at a CAGR of 10.84% from 2026 to 2035. The U.S. non-invasive cancer diagnostics market is increasing due to non-invasive cancer screening, with liquid biopsy, which detects cancer DNA from a simple blood test, allowing early detection.

Key Takeaways

• U.S. non-invasive cancer diagnostics sector pushed the market to USD 42.58 billion by 2026.
• Long-term projections show USD 107.53 billion valuation by 2035.
• Growth is expected at a steady CAGR of 10.84% in between 2026 to 2035
• By product type, the reagents & kits segment held the largest market share of 49% in 2025.
• By product type, the software & services segment held the market share of 20% in 2025, and is expected to grow at the fastest CAGR during the forecast period.
• By technology, the next-generation sequencing (NGS) segment held the largest market share of 28% in 2025.
• By technology, the liquid biopsy segment held the market share of 24% in 2025, and is expected to grow at the fastest CAGR during the forecast period.
• By cancer type, the breast cancer segment held the largest market share of 24% in 2025.
• By cancer type, the lung cancer segment held the U.S. non-invasive cancer diagnostics market share of 18% in 2025, and is expected to grow at the fastest CAGR during the forecast period.
• By application, the early cancer screening segment held the largest market share of 33% in 2025.
• By application, the recurrence monitoring segment held the market share of 14% in 2025, and is expected to grow at the fastest CAGR during the forecast period.
• By end use, the hospitals segment held the largest market share of 36% in 2025.
• By end use, the diagnostic laboratories segment held the market share of 29% in 2025, and is expected to grow at the fastest CAGR during the forecast period.

What Non-Invasive Cancer Diagnostics?

Non-invasive diagnostic technology that detects cancer by analysing biomarkers such as ctDNA and CTCs in blood or various fluids. Non-invasive diagnostic technology includes processes that assess the body’s internal condition without penetrating the skin or entering the body surgically. They influence advanced imaging, digital technologies, and spectroscopy to offer clear and precise insights into the physiological or pathological conditions. In the cancer diagnosis, non-invasive imaging processes involving PET, MRI, and CT are critical. With the applications of radioactive tracers, PET scans diagnose cancers and track the efficiency of treatment by identifying metabolic activity.  Non-invasive imaging allows real-time tracking of cancer response to medicines, enabling medical personnel to promptly adapt and enhance treatment plans.

AI Integration in China Central Lab

AI-powered technology in non-invasive cancer diagnostics has demonstrated up to 90 % precision in challenges identificantion via non-invasive processes. AI-based technology is helping to enhance the speed, correctness, and reliability of various cancer screening and identification processes. AI-driven image analysis enhances cancer identification, biomarker discovery, and diagnostic consistency. Multimodal AI strategy integrates data from radiology, pathology, and genomics to offer inclusive diagnostic insights.  This technology enhances diagnostic precision in radiology, pathology, dermatology, and ophthalmology by analysing images using applications of deep learning algorithms.

Future Outlook Trends in the U.S. Non-Invasive Cancer Diagnostics Market

• Liquid Biopsy Expansion: Liquid biopsy has increased traction because it offers easy access to cancer-derived biomarkers with lower potential challenges for patients than a medical biopsy.
• Multi-Cancer Early Detection (MCED): Multi-cancer early detection (MCED) testing has the potential to detect cancers at earlier, more treatable stages; identifying cancer even one stage earlier can lower mortality.
• At-Home and Point-of-Care Testing: The versatility, affordability, and ease of POCTs warrant attention for their strength to transform cancer identification, treatment, and diagnosis. They provide convenience, privacy, and, in some cases, may support identifying cancer earlier.

Executive Summary Table

Segmentation Analysis

By Product Type Insights

The Reagents & Kits Segment Led the U.S. Non-Invasive Cancer Diagnostics Market in 2025

The reagents & kits segment contributed the largest market share of 49% in 2025, as diagnostic reagents and kits identify diseases at an initial stage, and enhance treatment results. Molecular diagnosis determines the type of cancer and treatment approaches by detecting gene mutations in cancer cells.

The instruments segment held a significant share of 31% in the market, as instruments and analytical devices in cancer diagnostics transform oncology by allowing earlier identification, mapping exact cancer locations, and analysing tumors at the molecular level. Advanced tools detect ultra-low concentrations of tumor biomarkers from a single drop of blood or non-invasive fluid.

The software & services segment held a significant share of 20% in the market and is expected to grow at the fastest CAGR during the forecast period, as computing software plays a significant role in handling cancer big data by offering significant processing, infinite storage, accessibility, scalability, and affordability of computational resources. This software supports enhancing the speed, precision, and reliability of various cancer screening and detection methods.

By Technology Insights

Next-Generation Sequencing (NGS) Segment Led the U.S. Non-Invasive Cancer Diagnostics Market in 2025

The next-generation sequencing (NGS) segment contributed the largest market share of 28%, as next-generation sequencing (NGS) has evolved as a significant technology in the sector of oncology. NGS allows detailed genomic profiling of cancer, classifying genetic modifications that drive cancer progression and driving targeted treatment plans targeting particular mutations, therefore improving patient outcomes.

The liquid biopsy segment held a significant share of 24% of the market, and is expected to grow at the fastest CAGR during the forecast period, as liquid biopsies provides significant insights into tumor heterogeneity, treatment response, minimum residual disease identification, and targeted treatment of cancer via the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), microRNAs, and extracellular vesicles.

The polymerase chain reaction (PCR) segment held a significant share of 21% of the U.S. non-invasive cancer diagnostics market, as PCR identifies cancer marker-expressing cells that are otherwise undetectable by other methods in patients with localized or metastatic cancer. These tests allow physicians to research mutations resulting from a certain type of cancer. PCR classifies mutations and genetic markers that inform cancer diagnostics.

The imaging technology segment held a significant share of 18% of the market. These technologies improved healthcare imaging by enabling more precise cancer localization, staging, and treatment response monitoring, eventually enhancing patient outcomes, particularly in oncology. It also helps physicians find cancer, determine how far a cancer has spread, and guide the delivery of particular treatments.

By Cancer Type Insight

The Breast Cancer Segment led the U.S. Non-Invasive Cancer Diagnostics Market in 2025

The breast cancer segment held a significant share of 24% in the market. Non-invasive biomarkers like ctDNA, CTCs, and EVs hold significant promise for early identification and monitoring of breast cancer recurrence. It improves the accuracy of diagnosis. Timely screening improves treatment success, survival rates, and long-term health outcomes. By improving early diagnosis, liquid biopsy improves patient outcomes while lowering overall healthcare expenses.

The lung cancer segment contributed the largest market share of 18%, and is expected to grow at the fastest CAGR during the forecast period, as non-blood fluids provide a new, non-invasive choice for diagnosing lung cancer. Lung cancer patients could obtain more accurate treatment, and their development could be better tracked, using a novel high-tech process of non-invasive medical imaging analysis.

The colorectal cancer segment held a significant 13% share of the U.S. non-invasive cancer diagnostics market, as a non-invasive screening choice to make CRC detection rapid and easier. Innovative technologies, like the fecal occult blood test (FOBT), stool DNA testing, and blood-related biomarker assays, improve early identification and enhance patient results.

The prostate cancer segment held a significant share of 11% in the market, as the non-invasive tests renovate prostate cancer diagnosis by lowering technology and targeting biopsies to the highest-risk patients. Recent developments in biomarker tests show high specificity and negative prognostic value.

By Application Insights

The Early Cancer Screening Segment led the U.S. Non-Invasive Cancer Diagnostics Market in 2025

The early cancer screening segment contributed the largest market share of 33%, as early cancer detection is significant for efficient therapeutic intervention. Improves the capability to diagnose conditions at an early and treatable stage. Non-invasive technology is making cancer diagnostics less invasive and more effective.

The therapy selection segment held a significant share of 18% in the market, as non-invasive diagnostics offer actionable, highly accurate molecular and structural information without surgical incisions or tissue deletion. These safe, pain-free processes empower clinicians to pinpoint disease subtypes and track treatment effectiveness.

The treatment monitoring segment held a significant share of 17% in the U.S. non-invasive cancer diagnostics market, as non-invasive testing has evolved as a safer, more effective strategy for diagnostics, providing patients and medical care providers with alternatives to invasive procedures. These processes offer precise data related to the internal structures and organs of the body.

The recurrence monitoring segment held a significant share of 14% in the market, and is expected to grow at the fastest CAGR during the forecast period as non-invasive diagnostics lower complications, enable continuing monitoring, and more efficiently identify signs of treatment resistance and disease reappearance. It tracks disease dynamics with zero surgical trauma, allowing targeted therapy adjustments.

By End User Insights

The Hospitals Segment led the U.S. Non-Invasive Cancer Diagnostics Market in 2025

The hospitals segment contributed the largest market share of 36%, non-invasive tests provide various benefits over invasive practices, involving lower challenges of complications, reducing discomfort, and shortening recovery times. Doctors perform these tests externally or via minimally invasive processes.

The diagnostic laboratories segment held a significant share of 29% in the market, and is expected to grow at the fastest CAGR during the forecast period, due to the use of non-invasive processes for early cancer detection. Early identification is significant for efficient therapeutic intervention, and non-invasive processes have emerged as promising tools to improve diagnostic accuracy and enhance patient outcomes.

The cancer research institutes segment held a significant share of 14% in the U.S. non-invasive cancer diagnostics market, due to non-invasive processes for early cancer identification. Early detection is significant for efficient therapeutic intervention, and non-invasive technology evolves as a promising tool to improve diagnostic precision and improve patient outcomes.

The academic institutions segment held a significant share of 8% in the market, as non-invasive imaging provides a visual image of the tumor's size, type, and location, which is one of its significant benefits. This technology enhances screening and diagnostic effectiveness, and liquid biopsy supports enhance diagnostic precision and lower healthcare expenses.

Supply Chain Analysis

R&D

• Research and development in non-invasive cancer diagnostics focuses on biomarker discovery, liquid biopsy technologies, artificial intelligence integration, genomic sequencing, and assay optimization to improve early detection, accuracy, and oncology applications.
• Guardant Health, Illumina, Exact Sciences, Freenome, GRAIL, Natera, Bio-Rad Laboratories.

Clinical Trials & Regulatory Approvals

• Clinical trials and regulatory approvals validate non-invasive cancer diagnostic technologies through performance evaluations, patient studies, compliance documentation, and regulatory submissions, ensuring safety, reliability, commercialization readiness, and broader healthcare adoption globally.
• Roche, Thermo Fisher Scientific, Qiagen, Guardant Health, GRAIL, Exact Sciences, Foundation Medicine.

Latest Updates of Key Players in the U.S. Non-Invasive Cancer Diagnostics Market

SWOT Analysis

Strengths

• Non-invasive technology offers a targeted strategy to cancer identification, allowing the creation of therapy regimens that are significant to a patient’s individual genetic profile and cancer features. Advanced patient results are obtained from this focused strategy enhancement of therapeutic efficiency.
• Non-invasive processes cover a broad spectrum of advanced technology that reduce patient pain while revealing significant details on the existence, traits, and course of cancer.

Weakness

• Non-invasive technology is not able to identify or characterize tiny or subtle cancers with sufficient precision, which might result in false-negative or false-positive findings.

Opportunities

• Recent advancements in biosensing technologies allow incessant, real-time monitoring of age-associated biomarkers, marking a significant transformation from static measurements to dynamic health tracking.
• AI-based technology is supporting the enhancement of the speed, precision, and reliability of specific cancer screening and detection processes. This technology is transforming the way we identify cancer, making it rapid, more precise, and accessible.

Threat

• The increasing expenses and potential lack of availability of well-developed non-invasive imaging technologies in all medical care settings prevent their general use.

Recent Developments in the U.S. Non-Invasive Cancer Diagnostics Market

• In April 2026, Guardant Health, Inc. announced a multi-year strategic partnership with Nuvalent, Inc. to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity platform.
• In March 2026, Illumina, Inc. and Labcorp, a worldwide leader of innovative and comprehensive laboratory services, announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) services across the healthcare ecosystem.
• In December 2025, the Hackensack Meridian Hennessy Institute for Cancer Prevention and Applied Molecular Medicine announced an advanced collaboration with DELFI Diagnostics, supported by a Healthcare Improvement grant from Lilly to enhance lung-cancer screening adherence. 
• In November 2025, Oasis Diagnostics Corporation and UCM Technologies Announce Partnership to Enable At-Home Saliva Collection for Next-Generation Cancer Screening Test

Segments Covered in the Report

By Product Type

• Instruments
  • Sequencing Instruments
  • PCR Instruments
  • Imaging Systems
  • Flow Cytometry Systems
  • Microarray Systems
• Reagents & Kits
  • Assay Kits
  • Biomarker Reagents
  • Sample Preparation Kits
  • Sequencing Reagents
• Software & Services
  • Bioinformatics Software
  • AI-based Diagnostic Platforms
  • Data Analytics Services
  • Laboratory Services

By Therapeutic Area

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
  • Digital PCR
  • Real-Time PCR
• Liquid Biopsy
  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Exosomes
• Imaging Technology
  • MRI
  • CT
  • PET
  • Ultrasound
• Microarray Technology
• AI & Machine Learning-based Diagnostics

By Cancer User

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Cervical Cancer
• Blood Cancer
• Pancreatic Cancer
• Ovarian Cancer
• Other Cancers

By Sample Type

• Blood
• Urine
• Saliva
• Tissue-free Fluids
• Stool

By Application

• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring
• Prognostic Assessment
• Companion Diagnostics

By End User

• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Academic Institutions
• Specialty Clinics
• Ambulatory Surgical Centers